哮喘患者对抗白三烯治疗反应性的临床研究被引量：11

导出

摘要目的观察不同临床表型的哮喘患者对白三烯受体拮抗剂治疗反应性的差异,探讨预测治疗反应性的指标,为哮喘的个体化治疗提供依据。方法40例门诊哮喘患者,给予孟鲁司特10 mg口服,每晚1次,疗程30d,分别于治疗前与治疗后记录哮喘症状(ACQ)评分,测定1 s呼气容积(FEV1%),采集9∶00AM～3∶00PM、3∶00PM～12∶00PM、12∶00PM～9∶00AM 3段不同时间的尿液标本,测定标本中半胱氨酰白三烯E4(LTE4)浓度。结果抗白三烯治疗的敏感患者为10人(25%),不敏感者为11人(27.5%),中介者为19人(47.5%)。敏感组尿白三烯浓度高于中介组和不敏感组,敏感组患者治疗后1个月的FEV1%、ACQ评分、尿白三烯水平均有改善,与治疗前相比差异有统计学意义(P<0.05)。中介组和不敏感组治疗前后白三烯水平变化不明显。夜间哮喘、运动型哮喘与合并鼻炎哮喘对白三烯受体拮抗剂治疗反应较好,其中夜间哮喘对白三烯受体拮抗剂效果优于其他类型(P<0.05)。夜间哮喘患者夜间白三烯浓度高于白天(P<0.05)。结论白三烯水平高的哮喘患者对白三烯受体拮抗剂反应好;不同类型的哮喘患者对白三烯拮抗剂的反应性不同,其中夜间哮喘反应最好;夜间哮喘患者的夜间白三烯浓度较白天高,呈现昼夜节律性,而非夜间哮喘患者则未显示此昼夜节律。

作者吴永红刘春涛耿艳鸣朱涛

机构地区四川大学华西医院呼吸内科

出处《四川大学学报（医学版）》 CAS CSCD 北大核心 2008年第6期1049-1051,1055,共4页 Journal of Sichuan University(Medical Sciences)

关键词哮喘白三烯白三烯受体拮抗剂治疗反应性

分类号 R562.25 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献12

1Pefers SP. Leukotriene receptor antagonist in asthma therapy. J Allergy Clin Immunol,2003;111(1 Suppl):S62-70.
2Fabre JE, Goulet J, Riche E, et al. Transcellular binsynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J Clin Invest, 2002;109(10):1373-1380.
3National Institutes of Health, National Heart, Lung and Blood Institute. Global strategy for asthma management and prevention. Revised, 2006. http://www, ginasthma, corn/ Guideline item. asp.
4Obase Y, Shimoda T, Tomari SY, et al. Effects of pranlukast on chemical mediators in induced sputumon provocation tests in atopic and aspirin intolerant asthmatic patients. Chest,2002; 121(1) :143-150.
5Accomazzo MR, Rovati GE, Vigano T, et al. Leukotriene D4 induced activation of smooth muscle cells from human bronchi is partly Ca^2+ independent. Am J Respir Crit Care Med,2001; 163(1) :266-272.
6Thivierge M, Stankova J, RolaPleszczynski M. IL-13 and IL-4 upregulate cysteinyl leukotrienel receptor expression in human monocytes and macrophages. J Immunol, 2001 ; 167 (5) : 2855-2860.
7Montuschi P, Barnes PJ. Exhaled leukotrienes and prostaglandins in asthma. J Allergy Clin Immunol, 2002;109 (4):615-620.
8Mitsunobu F, Mifune T, Hosaki Y, et al. Enhanced peripheral leukocyte leukotriene production and bronchial hyperesponsiveness in asthmatics. Eur Respir J, 2000; 16 (3) : 504-508.
9Damen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, aleukotriene antagonist : a randomized, double-blind, placebocontrolled trial. Am J Respir Crit Care Med, 2002 ; 165 (1) : 9- 14.
10Joos L, Sandford AJ. Genotype predictors of response to asthma medications. Curt Opin Pulm Med, 2002 ; 8(1) : 9-11.